Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 16, 2012

 

 

Infinity Pharmaceuticals, Inc.

(Exact name of registrant as specified in charter)

 

 

 

Delaware   000-31141   33-0655706

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

780 Memorial Drive, Cambridge, MA   02139
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 453-1000

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨  

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨  

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨  

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨  

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

At our Annual Meeting of stockholders held on May 16, 2012 (the “Annual Meeting”), our stockholders approved Amendment No. 2 to our 2010 Stock Incentive Plan (the “2010 Plan”), which amendment had previously been adopted by our Board of Directors, subject to shareholder approval, to increase the number of shares of our common stock that may be issued pursuant to awards granted under the 2010 Plan by an additional 3,000,000 shares. A copy of this amendment is filed as Exhibit 99.1 hereto.

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

At the Annual Meeting, our stockholders voted on three matters as follows:

 

1. The following eleven nominees were elected to our Board of Directors to serve for a one-year term expiring at the 2013 annual meeting of stockholders:

 

     Votes For      Votes Against      Votes Abstaining      Broker Non-Votes  

Martin Babler

     15,654,822         738,195         7,124         1,757,948   

Anthony B. Evnin, Ph.D.

     15,653,605         739,413         7,123         1,757,948   

Gwen A. Fyfe, M.D.

     16,389,806         3,510         6,825         1,757,948   

Steven H. Holtzman

     16,002,042         395,444         2,655         1,757,948   

Eric S. Lander, Ph.D.

     16,057,484         337,954         4,703         1,757,948   

Patrick P. Lee

     15,655,136         740,314         4,691         1,757,948   

Thomas J. Lynch, M.D.

     16,055,413         337,904         6,824         1,757,948   

Adelene Q. Perkins

     16,057,276         340,510         2,355         1,757,948   

Norman C. Selby

     16,388,071         4,946         7,124         1,757,948   

Ian F. Smith

     16,054,894         340,472         4,775         1,757,948   

Michael C. Venuti, Ph.D.

     16,036,610         358,669         4,862         1,757,948   

 

2. Amendment No. 2 to our 2010 Plan was approved and an additional 3,000,000 shares of Common Stock were reserved for issuance thereunder.

 

Votes For

 

Votes Against

 

Votes Abstaining

 

Broker Non-Votes

11,368,629

  5,027,565   3,947   1,757,948

 

3. The appointment of Ernst & Young LLP as our independent registered public accounting firm for the current fiscal year was ratified.

 

Votes For

 

Votes Against

 

Votes Abstaining

 

Broker Non-Votes

18,148,670

  7,773   1,646  


Item 9.01. Financial Statements and Exhibits.

(d) The following exhibit is included in this report:

 

Exhibit

No.

   Description
99.1    Amendment No. 2 to 2010 Stock Incentive Plan


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    INFINITY PHARMACEUTICALS, INC.
Date: May 18, 2012     By:  

/s/ Gerald E. Quirk

      Gerald E. Quirk
      Vice President, Corporate Affairs and General Counsel